**Core Concept**
The initial treatment for Chronic Myeloid Leukemia (CML) is aimed at targeted therapy, which involves inhibiting the abnormal tyrosine kinase activity driven by the BCR-ABL fusion protein. Imatinib, a tyrosine kinase inhibitor (TKI), is the first-line treatment for CML due to its efficacy in inducing complete cytogenetic response.

**Why the Correct Answer is Right**
Imatinib works by selectively inhibiting the BCR-ABL tyrosine kinase, which is responsible for the uncontrolled proliferation of leukemic cells in CML. By blocking this enzyme, imatinib prevents the phosphorylation and activation of downstream signaling pathways, ultimately leading to the inhibition of cell growth and induction of apoptosis. The use of imatinib has revolutionized the treatment of CML, significantly improving patient outcomes and survival rates.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect as it does not represent a standard treatment approach for newly diagnosed CML patients.
**Option B:** This option is incorrect as it refers to a treatment typically used in acute lymphoblastic leukemia (ALL), not CML.
**Option C:** This option is incorrect as it is an older-generation TKI that has been largely replaced by more effective and better-tolerated agents like imatinib.

**Clinical Pearl / High-Yield Fact**
The introduction of imatinib has transformed the management of CML, shifting the disease from a fatal to a chronic condition in many patients. This marked a significant milestone in the history of CML treatment and highlights the importance of targeted therapy in oncology.

**Correct Answer: A. Imatinib**